The SRF114 program
SRF114 is a fully human, afucosylated anti-CCR8 antibody designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment. In pre-clinical studies, Surface Oncology has shown that SRF114 induces antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) pathways to deplete intertumoral Treg cells. In addition, SRF114 reduced tumor growth in murine models. These findings support the advancement of SRF114 as a therapeutic candidate that holds the potential to drive anti-tumor immunity in patients.
Compassionate Use Statement
Expanded access, or compassionate use, is the use of an investigational medicine prior to regulatory approval and outside of a clinical trial.
Surface Oncology does not currently have an expanded access program or compassionate use program for any of our investigational products.
We understand that for patients with serious diseases such as cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trial programs provides the best path to meet our goal of providing therapeutics to patients with cancer.
We encourage you to speak with your physician about options that may be right for you.